Skip to main content
Start triage

Start triage first, then route to emergency care.

Need urgent help? Start triage first, then route to emergency care.

Roxee Medication Guide

Polysulfated Glycosaminoglycan

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Liquid (Solution) American Regent, Inc. Official label facts Owner quick guide first

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts
Reference refreshed
Jun 22, 2026, 10:41 a.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
Jun 22, 2026, 10:41 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Jun 22, 2026, 10:42 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:41 AM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:40 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Jun 22, 2026, 10:41 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
Image coming soon
Polysulfated Glycosaminoglycan

Polysulfated Glycosaminoglycan

Drug type: Generic ingredient • Branded profile FDA branded products available

Both Liquid (Solution) Rx required 100% reference complete

Species: Both

Manufacturer: American Regent, Inc.

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Polysulfated Glycosaminoglycan

Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses. Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints. Species commonly shown: Both, Horse, Not For Meat Production, Adults.

Generic name
Polysulfated Glycosaminoglycan
Brand names
Adequan® Injectable, Adequan® i.m. Multi-Dose Adequan® i.m., Adequan® Canine, adequan i.m.
Manufacturer
American Regent, Inc.
Species
Both, Horse, Adults, Dog
Dosage forms
Liquid (Solution)
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Adequan® Injectable Adequan® i.m. Multi-Dose Adequan® i.m. Adequan® Canine adequan i.m. Adequan Canine
Dosage forms
Liquid (Solution)

Indications / Uses

Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses. Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

Warnings / Contraindications

Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Side Effects

Top reported reactions (openFDA): Vomiting, Diarrhoea, Lack of efficacy - NOS, Lethargy (see also Central nervous system depression in 'Neurological'), Not eating, Lethargy (see also Central nervous system depression in Neurological).

FAQ

Both, Horse, Not For Meat Production, Adults, Dog

Yes. Roxee shows this as prescription-only.

Liquid (Solution)

Source Transparency

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Not for use in horses intended for food
  • Safe use in breeding animals has not been established
  • Do not use in horses intended for human consumption
  • Safe use in breeding animals or in lactating mares has not been established
  • For Intramuscular use in horses only
  • Not for intra-articular use
  • Do not mix with other drugs or solvents
  • PSGAG is a synthetic heparinoid
  • do not use in dogs with known or suspected bleeding disorders
  • Do not exceed recommended dose or regimen
  • Vomiting (1 reports)
  • wobbly/unsteady walking (1 reports)
  • Loss of appetite (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?

Next actions

Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Polysulfated Glycosaminoglycan; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2025-US-072107
Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 26 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2025-US-072107
Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2025-US-072107
Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Vomiting (1 reports), Unsteady walking (ataxia) (1 reports), Loss of appetite (1 reports), Facial oedema (1 reports), Excessive chewing, licking and/or grooming (1 reports)

Body systems represented Signal grouping

Digestive (4), Neurologic (2), Behavior (1), Other (25)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Dog (26 reports), Cat (6 reports)

Breed metadata in reports Metadata only

Retriever - Labrador (2), Shepherd Dog - German (1), ['Retriever - Golden', 'Beagle', 'Chow Chow'] (1), Terrier - Irish Soft-coated Wheaten (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Polysulfated Glycosaminoglycan fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Not for use in horses intended for food, Safe use in breeding animals has not been established, Do not use in horses intended for human consumption, Safe use in breeding animals or in lactating mares has not been established, For Intramuscular use in horses only

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Polysulfated Glycosaminoglycan brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.
Vet source depth
  1. openFDA case USA-USFDACVM-2025-US-072107 · adverse_reaction · adverse reactions
  2. Contraindication source · fda_animal_drugs · warnings contraindications
  3. FDA application profile · official_label · quick facts
  4. FDA application profile · official_label · quick facts
  5. Medication usage source · fda_animal_drugs · quick facts
  6. FOI · document · documents
  7. SPL · document · documents
  8. FOI · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: February 12, 2026, 10:44 PM UTC

Sources:
Safety & side effects

Side effects to monitor:

  • Not for use in horses intended for food
  • Safe use in breeding animals has not been established
  • Do not use in horses intended for human consumption
  • Safe use in breeding animals or in lactating mares has not been established
  • For Intramuscular use in horses only

Most reported reactions:

  • Vomiting (1 reports)
  • Unsteady walking (ataxia) (1 reports)
  • Loss of appetite (1 reports)
Explore reported case details

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species
Adults, Dog, Horse
Indication / use
For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.
Form / route / dose
Form: Liquid (Solution)
Route: Intra-Articular, Intramuscular
Confirm product label and patient-specific plan.
Warnings
  • High: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts t…
Adverse-event caveat
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: American Regent, Inc.
Form: Liquid (Solution)
Identifiers:
NADA: 136383 NADA: 140901 NADA: 141038 NDC Package: 10797-959-01 NDC Package: 10797-975-01 NDC Package: 10797-975-02 NDC Package: 10797-995-01 NDC Package: 10797-995-70 NDC Product: 10797
Source metadata:

Warnings / Contraindications

Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • High: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Stored reports
14
Matching reports
3
Active filters
2
Selected filters
Reaction: Abnormal radiograph finding Clear Body system: Other Clear
Reset
Showing up to 50 matching reports.

USA-USFDACVM-2025-US-074601

Received 2025-12-16 · MSK · MSK

Serious
Species
Dog
Breed
Retriever - Labrador
Size / weight
50-99 lb (39.463 Kilogram)
Age
4-7 years (5 Year)
Sex
Male Neutered
Region
USA
Reactions
Limb non-weight bearingBone and joint disorder NOSOther abnormal test result NOSAbnormal radiograph findingUrinary tract obstruction/blockageDiscomfort NOSWalking difficultyDeath by euthanasiaOsteochondritis dissecansUrolithiasis
Body systems
Other
Outcomes
Euthanized

USA-USFDACVM-2025-US-072107

Received 2025-12-01 · MSK · MSK

Serious
Species
Dog
Breed
Shepherd Dog - German
Size / weight
50-99 lb (40.1 Kilogram)
Age
8+ years (10.5 Year)
Sex
Male Neutered
Region
USA
Reactions
VocalisationAbnormal tail posturePain NOSWeight lossDecreased appetiteVomitingChewing disorderPantingTremblingLying downAnxietyExcessive chewing, licking and/or groomingMuscle atrophy (see also Muscle wasting)Musculoskeletal disorder NOSAbnormal radiograph findingSpondylosisJoint effusionElevated gamma-glutamyl transferase (GGT)LymphopeniaLethargy (see also Central nervous system depression in Neurological)Thoracic painDeath by euthanasiaMedication error NOS
Body systems
OtherDigestiveBehaviorNeurologic
Outcomes
Euthanized

USA-USFDACVM-2025-US-069277

Received 2025-11-19 · MSK · MSK

Serious
Species
Cat
Breed
Domestic Shorthair
Size / weight
Under 10 lb (3.5 Kilogram)
Age
8+ years (16 Year)
Sex
Female Unknown
Region
USA
Reactions
Joint swellingBone and joint disorder NOSAbnormal radiograph findingPolyarthropathy NOS (see also PT Immune-mediated polyarthropathy)
Body systems
Skin & allergyOther
Outcomes
Ongoing

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
26
Species represented
2
Grouped by Body System
Digestive (4) · Vomiting, Loss of appetite, Diarrhea Neurologic (2) · Unsteady walking (ataxia), Depression Behavior (1) · Anxiety Other (25) · Falling, Facial oedema, Excessive chewing, licking and/or grooming
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Digestive 1 Dog 1
Neurologic 1 Dog 1
Digestive 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Cat 1

Species coverage: Dog (26) Cat (6)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Digestive Dog Serious - 1
Neurologic Dog Serious - 1
Digestive Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Digestive Cat Serious - 1
Neurologic Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Behavior Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Source metadata:

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

7

FOI

4

Adequan® Canine

SPL · SPL

FDA Structured Product Label

Adequan® Canine

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
American Regent, Inc.
NADA
141-038
Status
RX
Form
Liquid (Solution)
Route
Intramuscular
Species
Dog
Composition / specifications
Each mL of solution contains 100 mg polysulfated glycosaminoglycan.

Dogs

Indication
For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.
Dosage
2 milligrams per pound of body weight (0.02 mL/lb or 1 mL/ 50 lb) by intramuscular injection. Administer intramuscularly twice weekly for up to 4 weeks (maximum of 8 injections).
Limitations
PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Adequan® i.m. Multi-Dose

SPL · SPL

FDA Structured Product Label

Adequan® i.m. Multi-Dose Adequan® i.m.

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
American Regent, Inc.
NADA
140-901
Status
RX
Form
Liquid (Solution)
Route
Intramuscular
Species
Adults
Composition / specifications
Each mL of solution contains 100 milligrams polysulfated glycosaminoglycan available in 5-mL single dose ampules or 20-, 30-, or 50-mL multi-dose vials.

Horses

Indication
Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
Dosage
500 milligrams intramuscularly (carpal and hock) every 4 days for 28 days. Injection site must be thoroughly cleansed prior to injection.
Limitations
Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents.

Adequan® i.m.

SPL · SPL

FDA Structured Product Label

Adequan® i.m. Multi-Dose Adequan® i.m.

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
American Regent, Inc.
NADA
140-901
Status
RX
Form
Liquid (Solution)
Route
Intramuscular
Species
Adults
Composition / specifications
Each mL of solution contains 100 milligrams polysulfated glycosaminoglycan available in 5-mL single dose ampules or 20-, 30-, or 50-mL multi-dose vials.

Horses

Indication
Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
Dosage
500 milligrams intramuscularly (carpal and hock) every 4 days for 28 days. Injection site must be thoroughly cleansed prior to injection.
Limitations
Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents.

Adequan® Injectable

SPL · SPL

FDA Structured Product Label

Adequan® Injectable

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
American Regent, Inc.
NADA
136-383
Status
RX
Form
Liquid (Solution)
Route
Intra-Articular
Species
Horse
Composition / specifications
Each 1-milliliter ampule of sterile aqueous solution contains 250 milligrams of polysulfated glycosaminoglycan.

Horses

Indication
Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses.
Dosage
250 milligrams intra-articular use once a week for 5 weeks. The joint area must be shaved, cleaned, and sterilized as in a surgical procedure prior to injection. If the joint reacts with excessive inflammation, after intra-articular treatment, cease therapy.
Limitations
Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Adequan Canine SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Adequan Canine. Use the source link for the full official labeling record.

adequan i.m. SPL

SPL · Structured Product Label

FDA Structured Product Label XML for adequan i.m.. Use the source link for the full official labeling record.

Adequan i.m. SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Adequan i.m.. Use the source link for the full official labeling record.

N141038_Orig_7_15_1997.pdf

FOI · FOI

N140901_Supp_9_12_1996.pdf

FOI · FOI

N140901 Orig_11_11_1989.pdf

FOI · FOI

UCM367650.pdf

FOI · FOI

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:41 AM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:40 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Jun 22, 2026, 10:41 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Adequan Canine Adequan i.m. adequan i.m.
Manufacturer mapping: American Regent, Inc.
Case-reported brands (openFDA): MSK
Catalog species: Both FDA-labeled species: Adults, Dog, Horse
Rx/OTC: RX
Form/route: Liquid (Solution) Intra-Articular, Intramuscular
Applications: NADA 141-038 • NADA 140-901 • NADA 136-383
NDC: Packages 10797-959-01 10797-975-01 10797-975-02 10797-995-01 10797-995-70 Products 10797
Documents: 4 (FOI: 4) • SPL: 4 Label highlights Official documents
Safety (openFDA)
Top reactions: Dog 66 Cat 9 View
Case summaries: 14 (showing 8) View
openFDA reports are unverified and do not prove causation.

Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Vomiting (1) Unsteady walking (ataxia) (1) Loss of appetite (1) Facial oedema (1) Excessive chewing, licking and/or grooming (1) Elevated symmetrical dimethylarginine (1) Elevated gamma-glutamyl transferase (1) Elevated creatinine (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 136383 NADA: 140901 NADA: 141038 NDC Package: 10797-959-01 NDC Package: 10797-975-01 NDC Package: 10797-975-02 NDC Package: 10797-995-01 NDC Package: 10797-995-70 NDC Product: 10797
Package NDC Product NDC Form / Route Status
10797-959-01 10797 -
10797-975-01 10797 -
10797-975-02 10797 -
10797-995-01 10797 -
10797-995-70 10797 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • Adequan Canine SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • adequan i.m. SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Adequan i.m. SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • N141038_Orig_7_15_1997.pdf • FOI summary • Official • June 28, 2018
    FDA FOI summary for application 141038
  • N140901 Orig_11_11_1989.pdf • FOI summary • Official • Dec. 7, 2017
    FDA FOI summary for application 140901
  • N140901_Supp_9_12_1996.pdf • FOI summary • Official • Dec. 7, 2017
    FDA FOI summary for application 140901
  • UCM367650.pdf • FOI summary • Official • June 1, 2016
    FDA FOI summary for application 136383

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 126 Clinical 1 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): Vomiting, Diarrhoea, Lack of efficacy - NOS, Lethargy (see also Central nervous system depression in 'Neurological'), Not eat… (Clinical, 2026-04-11)
  • contraindications: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a … (Official, 2026-04-12)
  • contraindications: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a … (Official, 2026-04-11)
  • contraindications: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a … (Official, 2026-02-12)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-06-22)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-06-22)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-06-21)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-06-20)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-06-13)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-06-12)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-06-12)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-06-11)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-06-11)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-06-10)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-06-09)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-06-08)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-06-07)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-06-06)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-06-05)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-06-04)
Recent Revisions
  • side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Adequan® Canine
RX
Polysulfated Glycosaminoglycan
Liquid (Solution) Intramuscular
American Regent, Inc. NADA 141-038 Approved Jun 28, 2018
Adequan® i.m. Multi-Dose Adequan® i.m.
RX
Polysulfated Glycosaminoglycan
Liquid (Solution) Intramuscular
American Regent, Inc. NADA 140-901 Approved Dec 7, 2017
Adequan® Injectable
RX
Polysulfated Glycosaminoglycan
Liquid (Solution) Intra-Articular
American Regent, Inc. NADA 136-383 Approved Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog
Composition / specifications
Each mL of solution contains 100 mg polysulfated glycosaminoglycan.
Dogs
Indication
For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.
Dosage
2 milligrams per pound of body weight (0.02 mL/lb or 1 mL/ 50 lb) by intramuscular injection. Administer intramuscularly twice weekly for up to 4 weeks (maximum of 8 injections).
Limitations
PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Adults
Composition / specifications
Each mL of solution contains 100 milligrams polysulfated glycosaminoglycan available in 5-mL single dose ampules or 20-, 30-, or 50-mL multi-dose vials.
Horses
Indication
Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
Dosage
500 milligrams intramuscularly (carpal and hock) every 4 days for 28 days. Injection site must be thoroughly cleansed prior to injection.
Limitations
Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents.

FDA page: Open in Animal Drugs @ FDA

Species: Horse
Composition / specifications
Each 1-milliliter ampule of sterile aqueous solution contains 250 milligrams of polysulfated glycosaminoglycan.
Horses
Indication
Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses.
Dosage
250 milligrams intra-articular use once a week for 5 weeks. The joint area must be shaved, cleaned, and sterilized as in a surgical procedure prior to injection. If the joint reacts with excessive inflammation, after intra-articular treatment, cease therapy.
Limitations
Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Usage

Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses. Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Vomiting (1) • Dog Loss of appetite (1) • Dog Diarrhea (1) • Cat Decreased appetite (1) • Dog

Showing top 5 for Digestive.

Neurologic
Unsteady walking (1) • Dog Depression (1) • Dog

Showing top 5 for Neurologic.

Behavior
Anxiety (1) • Dog

Showing top 5 for Behavior.

Other
Falling (1) • Dog Facial oedema (1) • Dog Excessive chewing, licking and/or grooming (1) • Dog Eosinopenia (1) • Dog Elevated symmetrical dimethylarginine (1) • Cat
Show more (20)
Elevated globulins (1) • Dog Elevated gamma-glutamyl transferase (1) • Dog Elevated creatinine (1) • Cat Elevated blood urea nitrogen (1) • Dog Discomfort NOS (1) • Dog Difficulty standing (1) • Dog Dehydration (1) • Dog Decreased haematocrit (1) • Cat Decreased drinking (1) • Dog Decreased body temperature (1) • Dog Death by euthanasia (1) • Dog Death (1) • Dog Congestion of mucous membrane (1) • Dog Collapse NOS (1) • Dog Chewing disorder (1) • Dog Cardiac arrest (1) • Cat Bone and joint disorder NOS (1) • Cat Anaphylaxis (1) • Dog Abnormal tail posture (1) • Dog Abnormal radiograph finding (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Shepherd Dog - German, Female, 11 year, 20.865 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Vomiting, Not eating, Tiredness (lethargy), Reluctant to move, Seizure NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-075421
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Female
  • Age: 11.00 Year
  • Weight: 20.865 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Vomiting Not eating Tiredness (lethargy) Reluctant to move Seizure NOS
Outcomes: Ongoing

Dog, ['Retriever - Golden', 'Beagle', 'Chow Chow'], Male, 11 year, 19.504 kilogram • Drug: MSK, Unassigned, Subcutaneous, Frequency: 14 per day • Reactions: Unsteady walking (ataxia), Vestibular disorder NOS, Weight loss, Head tilt - neurological disorder, Low vision… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-075189
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 11.00 Year
  • Weight: 19.504 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Unassigned
  • Frequency: 14 per day
Reactions Reported:
Unsteady walking (ataxia) Vestibular disorder NOS Weight loss Head tilt - neurological disorder Low vision Urinary incontinence Unable to rise Urinary tract infection Polydipsia Horizontal nystagmus Generalised weakness Depression
Outcomes: Ongoing

Dog, Terrier - Irish Soft-coated Wheaten, Male, 12 year, 21.319 kilogram • Drug: MSK, Solution, Intramuscular, Dose: 0.90 mL per dose • Reactions: Death • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-074219
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Male
  • Age: 12.00 Year
  • Weight: 21.319 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Intramuscular
  • Form: Solution
  • Dose: 0.90 mL per dose
Reactions Reported:
Death
Outcomes: Died

Dog, Retriever - Chesapeake Bay, Female, 4 year, 35.743 kilogram • Drug: MSK, Solution, Intramuscular, Dose: 1.57 mL per dose • Reactions: Vomiting, Loss of appetite, Loose stool, Neutrophilia, Dehydration… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-074217
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 4.00 Year
  • Weight: 35.743 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Intramuscular
  • Form: Solution
  • Dose: 1.57 mL per dose
Reactions Reported:
Vomiting Loss of appetite Loose stool Neutrophilia Dehydration Low platelet count
Outcomes: Outcome Unknown

Dog, Retriever - Labrador, Male, 5 year, 39.463 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Limb non-weight bearing, Bone and joint disorder NOS, Other abnormal test result NOS, Abnormal radiograph finding, Urinary tract obstruction/blockage… • Outcome: Euthanized

  • Report ID: USA-USFDACVM-2025-US-074601
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 5.00 Year
  • Weight: 39.463 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Limb non-weight bearing Bone and joint disorder NOS Other abnormal test result NOS Abnormal radiograph finding Urinary tract obstruction/blockage Discomfort NOS Walking difficulty Death by euthanasia Osteochondritis dissecans Urolithiasis
Outcomes: Euthanized

Dog, Retriever - Labrador, Male, 11 year, 37.83 kilogram • Drug: MSK, Solution, Intramuscular, Dose: 1.60 mL per dose • Reactions: Anaphylaxis, Seizure NOS, Vomiting, Collapse NOS, Loose bowel… • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-073464
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 11.00 Year
  • Weight: 37.830 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Intramuscular
  • Form: Solution
  • Dose: 1.60 mL per dose
Reactions Reported:
Anaphylaxis Seizure NOS Vomiting Collapse NOS Loose bowel Congestion of mucous membrane Low blood pressure Decreased body temperature
Outcomes: Recovered/Normal

Dog, ['Pit Bull', 'Dog (unknown)'], Female, 11.5 year, 37.376 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Joint swelling, Bone and joint disorder NOS, Sarcoma NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074653
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 11.50 Year
  • Weight: 37.376 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Joint swelling Bone and joint disorder NOS Sarcoma NOS
Outcomes: Ongoing

Dog, Shepherd Dog - Australian, Male, 12.92 year, 11.79 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Tiredness (lethargy), Inappetence, Elevated blood urea nitrogen, Vomiting • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074767
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Male
  • Age: 12.92 Year
  • Weight: 11.790 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Tiredness (lethargy) Inappetence Elevated blood urea nitrogen Vomiting
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.